Glabellar Lines Pipeline Insight Research Report 2022 - ResearchAndMarkets.com

The "Glabellar Lines - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.

The "Glabellar Lines - Pipeline Insight, 2022" report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Glabellar Lines pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glabellar Lines collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

Companies and academics are working to assess challenges and seek opportunities that could influence Glabellar Lines R&D. The therapies under development are focused on novel approaches to treat/improve Glabellar Lines.

Glabellar Lines Emerging Drugs Chapters

This segment of the Glabellar Lines report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Glabellar Lines Emerging Drugs

Daxibotulinumtoxin A: Revance Therapeutics

Daxibotulinumtoxin A for Injection, is an investigational neuromodulator product. DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA and is currently under regulatory review. It is aiming to establish a new, premium, long-lasting neuromodulator category.

Daxibotulinumtoxin A combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. The FDA accepted for review the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection in the treatment of moderate to severe glabellar (frown) lines.

ATGC-100: EuBiologics

ATGC-100 is botulinum toxin A just like Allergan's Botox. Eubiologics and ATGC are jointly developing ATGC-100. Botulinum Toxin is a toxin produced only by the gram-positive anaerobic bacteria, Clostridium botulinum, inducing temporary muscle paralysis by reversibly blocking the secretion of acetylcholine at a neuromuscular junction

BoNTE: AbbVie

BoNTE is a toxin being investigated for treatment of glabellar lines. The drug is currently being investigated in phase 2 stage of development, for the treatment of glabellar lines.

IPN-10200: Ipsen

IPN-10200 , is a Longer-acting neurotoxin. IPN-10200 is currently being investigated in Phase I/II. The purpose of this study is to assess the safety and efficacy profile of increasing doses of IPN10200 in comparison to placebo, with the aim to discover the doses(s) that offer the best efficacy/safety profile when used for the treatment of moderate to severe Upper Facial Lines.

AI-09: Eirion Therapeutics

Eirion is developing a next generation ready-to-use liquid injectable neuromodulator product called AI-09 for the treatment of glabellar (frown) lines. Eventually, AI-09 may be developed for other aesthetic and medical indications. AI-09 will be provided as a ready-to-use, liquid formulation, which contrasts favorably to currently commercialized neuromodulator products that all require reconstitution with saline in the physician's office before use.

As well, in contrast to current injectable products, AI-09 does not contain human albumin, which carries a risk of disease transmission. AI-09 have been shown to be stable at room temperature for at least 3 months, which is also an advantage over current products that require shipping to and storage at the physician's office in frozen conditions. Eirion plans to file an IND for AI-09 later this year.

Glabellar Lines: Therapeutic Assessment

This segment of the report provides insights about the different Glabellar Lines drugs segregated based on the following parameters that define the scope of the report, such as:

Key Questions

• How many companies are developing Glabellar Lines drugs?
• How many Glabellar Lines drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Glabellar Lines?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Glabellar Lines therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Glabellar Lines and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Revance Therapeutics
• ATGC Biotech
• AbbVie
• Ipsen
• Eirion Therapeutics
• Shanghai Fosun Pharmaceutical

Key Products

• ATGC-100
• BONTE
• IPN-10200
• AI-109
• Daxibotulinumtoxin A
• QM1114

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/xytdp4

View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005773/en/